Aardvark Therapeutics, Inc. (AARD) stock
AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.33−0.19 (-12.50%)
Close on Nov 13, 2026Market cap $29.11MP/E –Yield –
Aardvark Therapeutics cash
Cash and short-term investments held at the end of each period.
Aardvark Therapeutics's cash was $60.30M at Sep 30, 2026. For fiscal 2025 it was $110.00M, up 49.3% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.00M | +49.3% |
| FY2024 | Dec 31, 2024 | $73.66M | +656.7% |
| FY2023 | Dec 31, 2023 | $9.74M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $60.30M | -52.3% |
| Q2 FY2026 | Jun 30, 2026 | $73.90M | -47.9% |
| Q1 FY2026 | Mar 31, 2026 | $91.20M | -39.7% |
| Q4 FY2025 | Dec 31, 2025 | $110.00M | +49.3% |
| Q3 FY2025 | Sep 30, 2025 | $126.40M | +53.6% |
| Q2 FY2025 | Jun 30, 2025 | $141.80M | +64.6% |
| Q1 FY2025 | Mar 31, 2025 | $151.30M | +1906.6% |
| Q4 FY2024 | Dec 31, 2024 | $73.66M | +656.7% |
| Q3 FY2024 | Sep 30, 2024 | $82.28M | – |
| Q2 FY2024 | Jun 30, 2024 | $86.17M | – |
| Q1 FY2024 | Mar 31, 2024 | $7.54M | – |
| Q4 FY2023 | Dec 31, 2023 | $9.74M | – |
See a number that looks wrong?